1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,870 | 0,910 | 13:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.07. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.07. | LakeShore Biopharma announces $15M private placement financing | 1 | Seeking Alpha | ||
| 08.07. | LakeShore Biopharma secures $15 million in private placement | 1 | Investing.com | ||
| 06.05. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.03. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.03. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 19.12.24 | LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance | 169 | PR Newswire | Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY
Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY
Gross margin... ► Artikel lesen | |
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.12.24 | LakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China | 203 | GlobeNewswire (Europe) | BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a leading global biopharmaceutical company focused on the innovation... ► Artikel lesen | |
| 25.10.24 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine | 563 | PR Newswire | GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical... ► Artikel lesen | |
| 10.10.24 | XFRA H6Z0: WIEDERAUFNAHME/RESUMPTION | 259 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 08.10.24 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance | 217 | PR Newswire | GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering... ► Artikel lesen | |
| 04.10.24 | XFRA H6Z0: AUSSETZUNG/SUSPENSION | 391 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLAKESHORE BIOP.... ► Artikel lesen | |
| 04.10.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 04.10.2024 | 468 | Xetra Newsboard | The following instruments on XETRA do have their first trading 04.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 04.10.2024
Aktien
1 US59564R8079 Biodexa Pharmaceuticals... ► Artikel lesen | |
| 03.10.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.10.2024 | 605 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.10.2024ISIN NameUS59564R7089 BIODEXA... ► Artikel lesen | |
| 03.10.24 | XFRA ISIN CHANGE | 769 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA3874371147 Granite REIT LP 03.10.2024 CA3874372053 Granite REIT LP 04.10.2024 Tausch 1:1US86323X1063 Streamline... ► Artikel lesen | |
| 01.10.24 | XFRA H6Z: AUSSETZUNG/SUSPENSION | 321 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLAKESHORE BIOP.DL-... ► Artikel lesen | |
| 27.09.24 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation | 292 | PR Newswire | GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering... ► Artikel lesen | |
| 15.08.24 | LakeShore Biopharma Co., Ltd: LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 | 671 | PR Newswire | Gross margin increased to 79.5%; product pipeline continues to advance
Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025
GAITHERSBURG,... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,262 | -16,01 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| NUVALENT | 83,40 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| IMMUNOVANT | 17,910 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,845 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| SUMMIT THERAPEUTICS | 26,200 | 0,00 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| AVIDITY BIOSCIENCES | 33,740 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| ARVINAS | 7,350 | 0,00 % | Arvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan | - John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor - - Dr. Houston to Remain Chairperson of Arvinas Board of Directors... ► Artikel lesen | |
| TELOMIR PHARMACEUTICALS | 2,300 | 0,00 % | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
| VERVE THERAPEUTICS | 10,915 | 0,00 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
| ADMA BIOLOGICS | 16,730 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,500 | 0,00 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
| CRISPR THERAPEUTICS | 58,00 | +3,57 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| TARSUS PHARMACEUTICALS | 43,250 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| QIAGEN | 41,495 | +0,22 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| PROKIDNEY | 3,150 | 0,00 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen |
LAKESHORE BIOPHARMA CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,805 Euro und damit -8,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.